Frontiers in oncology
A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory mantle cell lymphoma
By Malhotra P, Bhurani D, Sengar M and 13 others.
Abstract
Objective
To evaluate the safety and clinical outcomes of acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or refractory/relapsed mantle cell lymphoma (MCL) in a real-world setting in India.
